European Growth Hormone Market size is estimated to reach USD 1.6 billion by 2027, according to a latest forecast report by Graphical Research.
Growth hormone, also known as somatotropin, helps to regulate muscle and bone growth, body fluids, sugar and fat metabolism, heart function as well as body composition. Growth hormone (GH) and placental lactogen are pituitary hormones that regulates a wide range of important physical functions and are used to treat many conditions including growth failure, short stature and low GH levels among others that fosters the market demand. Growth hormone deficiency is a rare disease characterized by the inadequate secretion of growth hormone from the pituitary gland and affects one in around 4,000 to 10,000 people. In children, this disease can be caused by genetic mutations or can be acquired after birth as pituitary gland secretes inadequate levels of somatropin. Therefore, above-mentioned aspects proves beneficial for the overall industry progression. However, side effects associated with the treatment of growth hormone deficiency, turner syndrome and Prader-Willi syndrome limits the market expansion.
The powder segment accounted for around USD 642 million revenue in 2020. Powder form is the most used form in which the growth hormones are supplied. Few of the foremost players manufacturing growth hormones in powder form are Ferring Pharmaceuticals (Zomacton), Eli Lilly and Company (Humatrope), Merck (Saizen) as well as Pfizer (Genotropin).
Browse detailed statistical insights from the report, “Europe Growth Hormone Market Forecast 2027 By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Medstores), By Product (Powder, Solvent), By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome), Research Report, Country Outlook (Germany, France, UK, Italy, Spain, Russia, Netherlands, Denmark, Poland), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
The Prader-Willi syndrome segment held more than 5.5% market share in 2020. Prader-Willi Syndrome (PWS) is a rare neurodevelopmental condition caused by a genetic mutation with a complex phenotypic that changes with age. PWS is caused due to chromosome 15 defect that arises around the time of pregnancy and currently has no specific cure. According to the Prader-Willi Syndrome Association UK, approximately 1500 to 2000 people of all ages in the UK have PWS.
The online medstore segment dominated around 11.5% market share in 2020, owing to the rising popularity of online medstore and internet penetration. As the shift from offline to online continues, healthcare enterprises in southern European countries such as France, Germany, Italy, and Spain will have significant development potential. Due to rising knowledge of online over-the-counter benefits and high-speed internet availability the demand for online medstore is increasing thereby, accelerating the market growth.
Germany growth hormone market is projected to witness over 6.7% CAGR during the forecast period owing to rising demand for growth hormone therapies for the treatment of GH deficiency coupled with increasing product launches. For instance, in August 2020, Novo Nordisk’s received the FDA approval for Sogroya, a TransCon hGH in the Europe for the treatment of adult GHD.
European growth hormone market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:
Europe Market, By Product
Europe Market, By Application
- Growth Hormone Deficiency
- Idiopathic Short Stature
- Turner Syndrome
- Small For Gestational Age
- Prader-Willi Syndrome
Europe Market, By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Medstores
The above information has been provided for the following countries: